Medtronic (NYSE:MDT) said today its Medtronic Canada subsidiary received Health Canada approval for its line of MRI-conditional cardiac resynchronization therapy defibrillators, touting them as the 1st MRI CRT-Ds cleared in the region.
With the new clearance, Fridley, Minn.-based Medtronic’s Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems, which are currently available in the region, are cleared for MRI scans of any part of the body without positioning restrictions.
Both newly cleared devices can be paired with the company’s Attain Performa MRI SureScan quadripolar leads, Medtronic said.
“The ability to undergo an MRI scan is a vital consideration for patients. Our CRT-D class of devices provides a comprehensive range of options for physicians, and removes the barrier to MRIs for heart failure. Together with the rest of our proven MRI conditional portfolio, we continue delivering on our commitment to provide cardiac patients with the latest technology,” Medtronic Canada cardiac & vascular group senior director Michael Blackwell said in a press release.
Last week, Medtronic reiterated its previous full fiscal year guidance in light of an information technology system malfunction in June, saying that the disruption along with other circumstances have moved their 4-5% growth rate to the lower end of the range for their fiscal 1st quarter.